皮肤隆突性纤维肉瘤2022.v1-NCCN(英文版)_第1页
皮肤隆突性纤维肉瘤2022.v1-NCCN(英文版)_第2页
皮肤隆突性纤维肉瘤2022.v1-NCCN(英文版)_第3页
皮肤隆突性纤维肉瘤2022.v1-NCCN(英文版)_第4页
皮肤隆突性纤维肉瘤2022.v1-NCCN(英文版)_第5页
已阅读5页,还剩31页未读 继续免费阅读

下载本文档

版权说明:本文档由用户提供并上传,收益归属内容提供方,若内容存在侵权,请进行举报或认领

文档简介

NCCNClinicalPracticeGuidelinesinOncologyNCCNGuidelines®)DermatofibrosarcomaProtuberansersionNovemberVersion1.2022,11/17/21©2021NationalComprehensiveCancerNetwork(NCCN),Allrightsreserved.NCCNGuidelinesandthisillustrationmaynotbereproducedinanyformwithouttheexpresswrittenpermissionofNCCN.PrintedbyMinTangon3/14/20227:31:17AM.Forpersonaluseonly.Notapprovedfordistribution.Copyright©2022NationalComprehensiveCancerNetwork,Inc.,AllRightsReserved.uberansdexChrysalyneD.Schmults,MD,MS/Chairϖ¶Dana-Farber/BrighamandWomen’senterRachelBlitzblau,MD,PhD/ViceChair§DukeCancerInstituteSumairaZ.Aasi,MDϖStanfordCancerInstituteMuradAlam,MD,MBA,MSCIϖ¶ζRobertH.LurieComprehensiveCancerCenterofNorthwesternUniversityJamesS.Andersen,MD¶ŸCityofHopeNationalMedicalCenterBrianC.Baumann,MD§SitemanCancerCenteratBarnes-JewishHospitalandWashingtonUniversitySchoolofMedicineJeremyBordeaux,MD,MPHϖCaseComprehensiveCancerCenter/UniversityHospitalsSeidmanCancerCenterandClevelandClinicTaussignstitutePei-LingChen,MD,PhD≠MoffittCancerCenterRobertChin,MD,PhD§UCLAJonssonComprehensiveCancerCenterCarloM.Contreras,MD¶TheOhioStateUniversityComprehensiveCancerCenter-JamesCancerHospitalandSoloveResearchInstituteDominickDiMaio,MD≠Fred&PamelaBuffettCancerCenternesPanelDisclosuresJessicaM.Donigan,MDϖHuntsmanCancerInstituteattheUniversityofUtahJeffreyM.Farma,MD¶FoxChaseCancerCenterMaxwellA.Fung,MDϖ≠UCDavisComprehensiveCancerCenterKarthikGhosh,MDÞCancerCenterRoyC.Grekin,MDϖ¶UCSFHelenDillerFamilyComprehensiveCancerCenterKellyHarms,MD,PhDϖUniversityofMichiganRogelCancerCenterAlanL.Ho,MD,PhD†MemorialSloanKetteringCancerCenterAshleyHolder,MD¶O’NealComprehensiveCancerCenteratUABJohnNicholasLukens,MD§AbramsonCancerCenterattheUniversityofPennsylvaniaTheresaMedina,MD†UniversityofColoradoCancerCenterKishwerS.Nehal,MDϖ¶MemorialSloanKetteringCancerCenterPaulNghiem,MD,PhDϖFredHutchinsonCancerResearchCenter/SeattleCancerCareAllianceSooPark,MD†UCSanDiegoMooresCancerCenterTejeshPatel,MDϖ≠St.JudeChildren’sResearchHospital/UniversityofTennesseeHealthScienceIgorPuzanov,MD,MSCI†RoswellParkComprehensiveCancerCenterJeffreyScott,MD,MHSϖTheSidneyKimmelComprehensiveCancerCenteratJohnHopkinsAleksandarSekulic,MD,PhDϖMayoClinicCancerCenterAshokR.Shaha,MD¶ζMemorialSloanKetteringCancerCenterDivyaSrivastava,MDϖUTSouthwesternSimmonsComprehensiveCancerCenterWilliamStebbins,MDϖ¶Vanderbilt-IngramCancerCenterValenciaThomas,MDϖTheUniversityofTexasYaohuiG.Xu,MD,PhDϖUniversityofWisconsineCancerCenterBDermatologyÞInternalmedicine†MedicaloncologyζOtolaryngology≠Pathology/DermatopathologyŸReconstructivesurgery§Radiotherapy/Radiationoncology¶Surgery/Surgicaloncology*DiscussionSectionWritingCommitteeVersion1.2022,11/17/21©2021NationalComprehensiveCancerNetwork(NCCN),Allrightsreserved.NCCNGuidelinesandthisillustrationmaynotbereproducedinanyformwithouttheexpresswrittenpermissionofNCCN.PrintedbyMinTangon3/14/20227:31:17AM.Forpersonaluseonly.Notapprovedfordistribution.Copyright©2022NationalComprehensiveCancerNetwork,Inc.,AllRightsReserved.uberansdexlievesthatthebestlievesthatthebestmanagementforanypatientwithcancerisinaclinicaltrial.Participationinclinicaltrialsisespe-ciallyencouraged.FindanNCCNMemberInstitution:/home/member-institutions/.ofEvidenceandsusAllrecommendationsotherwiseindicated.ategoriesofEvidenceandConsensus.aryoftheGuidelinesUpdatesPresentationandWorkupDFSPentandFollowupDFSPPathologyDFSPAExcisionDFSPBiationTherapyDFSPCTheNCCNGuidelinesareastatementofevidenceandconsensusoftheauthorsregardingtheirviewsofcurrentlyacceptedapproachestotreatmentAnyclinicianseekingtoapplyorconsulttheNCCNGuidelinesisexpectedtouseindependentmedicaljudgmentinthecontextofindividualstancestodetermineanypatientscareortreatmentTheNationalComprehensiveCancerNetworkNCCNmakesnorepresentationsorwarrantiesofanykindregardingtheircontentuseorapplicationanddisclaimsanyresponsibilityfortheirapplicationoruseinanywayTheNCCNbereproducedinanyformwithouttheexpresswrittenpermissionofNCCN.©2021.Version1.2022,11/17/21©2021NationalComprehensiveCancerNetwork(NCCN),Allrightsreserved.NCCNGuidelinesandthisillustrationmaynotbereproducedinanyformwithouttheexpresswrittenpermissionofNCCN.UPDATESVersion1.2022,11/17/21©2021NationalComprehensiveCancerNetwork(NCCN),Allrightsreserved.NCCNGuidelinesandthisillustrationmaynotbereproducedinanyformwithouttheexpresswrittenpermissionofNCCN.PrintedbyMinTangon3/14/20227:31:17AM.Forpersonaluseonly.Notapprovedfordistribution.Copyright©2022NationalComprehensiveCancerNetwork,Inc.,AllRightsReserved.uberansdexsionoftheNCCNGuidelinesforDermatofibrosarcomaProtuberansfromVersionincludenicalPresentationpWorkup,fourthbulletrevised:ConsiderpreoperativeMRIwithcontrastfortreatmentplanningifextensiveextracutaneoussubcutaneousextensionorarecurrenttumorissuspected.•Footnoteb,lastsentenceremoved:Biopsyclosuresareencouragedtobekeptsmallsoasnottodistorttheanatomyfordefinitiveexcision.•Footnotedrevised:Iffibrosarcomatouschanges/malignanttransformationsareisnotedfound,multidisciplinaryconsultationforconsiderationoffurthertreatmentandsurveillanceisrecommended.SeetheNCCNGuidelinesforSoftTissueSarcomaformultimodaltherapyandsurveillanceconsiderations.Multidisciplinaryconsultationisrecommendedforotherhigh-riskfeatures.(AlsopageDFSP-2)DFSP-2•TreatmentpHeaderrevised:ExcisionwithMohsmicrographicsurgery(MMS)orotherformsofCCPDMAperipheralanddeepenfacemarginassessment(PDEMA).•RevisedfootnotespFootnotee:Themostcommonlyusedformofcompletecircumferentialperipheralanddeepmarginassessment(CCPDMA)PDEMAisMohs(MMS).SeeNCCNGuidelinesforSquamousCellSkinCancer-PrinciplesofCCPDMAPDEMATechnique.IfCCPDMAisunavailable,theriskofconcealingresidualtumorbelowimmobilizedtissue.SeePrinciplesofExcision(DFSP-B).Whenanatomicstructuresatthedeepmargin(eg,majorvessels,nerves,bone)precludecompletehistologicevaluationofthemarginalsurfaceviaMohsorotherformsofPDEMA,MohsorotherformsofPDEMAshouldbeusedtoevaluateasmuchofthemarginalsurfaceasfeasible.Treatmentconsiderationsfornon-visualizedareasmaybethesubjectofmultidisciplinarydiscussion.pFootnoteg:Considerneoadjuvantimatinibforpatientsinwhomresectionwithnegativemarginsmayresultinunacceptablefunctionalorcosmeticoutcomes.isnotanticipatedtoachievenegativemarginswithoutunacceptablefunctionalorcosmeticoutcomes.UgurelS,etal.ClinCancerRes2014;20:499-510.pFootnotej:FornegativemarginsWhenMohsorotherformsofPDEMAareutilized,RTisnotrecommended.WhenMohsorotherformsofPDEMAarenotutilized,considerRTifmarginsare<1cm.RTcanbeconsideredfortreatmentofpositivemarginsifnotgivenpreviouslyandfurtherresectionisnotfeasible.pFootnotek:Tumorslackingthet(17;22)rearrangementmaynotrespondtoimatinib.Cytogeneticanalysis(molecularorconventional)ofatumormaybeusefulpriortotheinstitutionofimatinibtherapy.Navarrete-DechentC,etal.JAMADermatol2019;155:361-369.•Footnotefadded:IfPDEMAisunavailable,considerwideexcision.Wideunderminingisdiscouragedpriortoconfirmationofclearmarginsduetothedifficultyofinterpretingsubsequentre-excisedmargins,andtheriskofconcealingresidualtumorbelowmobilizedtissue.SeePrinciplesofExcision(DFSP-B).UPDATESVersion1.2022,11/17/21©2021NationalComprehensiveCancerNetwork(NCCN),Allrightsreserved.NCCNGuidelinesandthisillustrationmaynotbereproducedinanyformwithouttheexpresswrittenpermissionofNCCN.PrintedbyMinTangon3/14/20227:31:17AM.Forpersonaluseonly.Notapprovedfordistribution.Copyright©2022NationalComprehensiveCancerNetwork,Inc.,AllRightsReserved.uberansdexsionoftheNCCNGuidelinesforDermatofibrosarcomaProtuberansfromVersioninclude•PrinciplesofPathologypFirstbulletrevised:Evaluationbyaqualifiedphysicianwithspecificexpertiseinsarcoma/softtissuepathologyordermatopathologyispreferred(ifavailable).pFourthbulletrevised:Fibrosarcomatoustransformation(FS-DFSP)isreflectedbycharacterizedbytransitionfromstoriformtoaherringbonepattern,withahigherdegreeofcellularity,cytologicatypia,mitoticactivity(>5/10high-powerfields[HPF]),andnegativefrequentlossofCD34immunostaining.pSixthbulletrevised:Margincontrolduringexcision(seePrinciplesofExcision)mayrequireoccasionallybeaidedbyH&EsectionssupplementedbyCD34immunohistochemistry.•Footnote2revised:FS-DFSPshouldbenotedwhenpresentasthemetastaticriskis15%–20%andthepatientshouldbereferredtoacenterwithexpertiseinmanagementofsofttissuesarcomas.asitisassociatedwithapoorprognosis.DFSP-B•PrinciplesofExcisionpGoal,bulletrevised:Everyeffortshouldbemadetoachieveclearsurgicalmargins.Completehistologicsurgicalmarginexaminationtoincludereviewoftheentireexcisedperipheralanddeepmarginisrecommended,wheneverpossible.Tumorcharacteristicsincludelong,irregular,subclinicalextensions.DebulkingSspecimensfromdebulking/Mohsallexcisionsshouldbeexaminedtoidentifyfibrosarcomatoustransformation(FS-DFSP)sincethisisassociatedwithmetastaticpotential.pSurgicalapproach,headingrevised:MohsMicrographicSurgeryorOtherFormsofCCPDMAPDEMA.◊Firstbulletrevised:SeeNCCNGuidelinesforSquamousCellSkinCancer-PrinciplesofCCPDMAPDEMATechnique.◊Secondbulletrevised:IfCCPDMAMohsorotherformsofPDEMAareunavailable,considerwideexcision.–Firstsub-bulletremoved:Ifthereisconcernthatthesurgicalmarginsarenotcompletelyclear,consideravoidingrepairwithaflaporothertechnique,asitmayimpedemonitoringofthesiteanddelaydetectionofarecurrence.Split-thicknessskingrafting(STSG)maybeconsidered.–Secondsub-bulletremoved:Itisrecommendedthatanyreconstructioninvolvingextensiveunderminingortissuemovementbeavoidedordelayeduntilnegativehistologicmarginsareverifiedtopreventsubclinicaltumorpersistence,particularlyinadvertentconcealmentofresidualtumorbelowrepositionedtissueorarepair.–Newsub-bulletadded:Reconstructionshouldbedelayeduntilclearmarginshavebeenverifiedtoavoidtheriskoftranslocatingtumorwithintheresectionbedmakingfurthermarginassessmentsinaccurate.DFSP-C•PrinciplesofRTpGeneralTreatmentInformation,AdjuvantRT,Negativemargins:◊Firstsub-bulletrevised:WhenMohsorotherformsofPDEMAareutilized,RTisnotrecommended.◊Newsub-bulletadded:WhenMohsorotherformsofPDEMAarenotutilized,considerRTifmarginsare<1cm.FSPforskincanceransiderpreoperativeMRIwithcontrastfortreatmentplanningifensivesubcutaneousextensionisctedPrintedbyMinTangon3/14/20227:31:17AM.ForpersonaluseFSPforskincanceransiderpreoperativeMRIwithcontrastfortreatmentplanningifensivesubcutaneousextensioniscteduberansdexCLINICALPRESENTATIONWORKUPHPybcybcpHematoxylinandeosin(H&E)pImmunopanel(eg,CD34,factorXIIIa)eorotherhigheorotherhighriskfeaturesdAsdecisionsaboutdiagnosisandresectionmaybemultidisciplinaryltationatacenterwithcializedexpertiseshouldonsideredespeciallyforlargeoraFormoreinformation,seeAmericanAcademyofDermatologyAssociation.bThistumorisfrequentlymisdiagnosedduetoinadequatetissuesampling/superficialbiopsy.Punch,incisional,orcorebiopsy,preferablyincludingthedeepersubcutaneouslayer,isstronglyrecommendedforsufficienttissuesamplingandaccuratepathologicassessment.Ifbiopsyisindeterminateorclinicalsuspicionremains,rebiopsyisrecommended.Wideunderminingisdiscouragedduetothedifficultyofinterpretingsubsequentre-excisionspathologically.cPrinciplesofPathology(DFSP-A).dIffibrosarcomatoustransformationisfound,multidisciplinaryconsultationforconsiderationoffurthertreatmentandsurveillanceisrecommended.SeetheNCCNGuidelinesforSoftTissueSarcomaformultimodaltherapyandsurveillanceconsiderations.Note:Allrecommendationsarecategory2Aunlessotherwiseindicated.ClinicalTrials:NCCNbelievesthatthebestmanagementofanypatientwithcancerisinaclinicaltrial.Participationinclinicaltrialsisespeciallyencouraged.DFSP-1Version1.2022,11/17/21©2021NationalComprehensiveCancerNetwork(NCCN),Allrightsreserved.NCCNGuidelinesandthisillustrationmaynotbereproducedinanyformwithouttheexpresswrittenpermissionofNCCN.PrintedbyMinTangon3/14/20227:31:17AM.Forpersonaluseonly.Notapprovedfordistribution.Copyright©2022NationalComprehensiveCancerNetwork,Inc.,AllRightsReserved.uberansdexTREATMENTsurgicalsurgicalwithMohsorotherformsofperipheralanddeepenfacemargin(PDEMA)(PDEMA)d,e,f,gsurgeryNegativeuntilmarginsionefuntilmarginsPositiveatmentAatmentTREATMENTObservationMultidisciplinaryconsultationforofRTofRTh,jvs.dIffibrosarcomatoustransformationisfound,multidisciplinaryconsultationforconsiderationoffurthertreatmentandsurveillanceisrecommended.SeetheNCCNGuidelinesforSoftTissueSarcomaformultimodaltherapyandsurveillanceconsiderations.eThemostcommonlyusedformofPDEMAisMohs.SeeNCCNGuidelinesforSquamousCellSkinCancer-PrinciplesofPDEMATechnique.Whenanatomicstructuresatthedeepmargin(eg,majorvessels,nerves,bone)precludecompletehistologicevaluationofthemarginalsurfaceviaMohsorotherformsofPDEMA,MohsorotherformsofPDEMAshouldbeusedtoevaluateasmuchofthemarginalsurfaceasfeasible.Treatmentconsiderationsfornon-visualizedareasmaybethesubjectofmultidisiplinarydiscussion.fIfPDEMAisunavailable,considerwideexcision.Wideunderminingisdiscouragedpriortoconfirmationofclearmarginsduetothedifficultyofinterpretingsubsequentre-excisedmargins,andtheriskofconcealingresidualtumorbelowmobilizedtissue.SeePrinciplesofExcision(DFSP-B).FOLLOW-UP•Physicalexamwithfocusonprimarysiteonthsievery6–onthsittionoutregularxamTHERAPYFORRECURRENCE/METASTASISerredeferredefRThjifnotgivenpreviouslysectionnotfeasibleatinibkswherediseasenresectableRThjifnotgivenpreviouslysectionnotfeasibleconsultationlconsultationlgConsiderneoadjuvantimatinibforpatientsinwhomresectionwithnegativemarginsmayresultinunacceptablefunctionalorcosmeticoutcomes.UgurelS,etal.ClinCancerRes2014;20:499-510.hSeePrinciplesofRadiationTherapy(DFSP-C).iMRIwithcontrastmaybehelpfultodetectearlyrecurrenceinpatientswithhigh-risklesionsordelineatetumorextentwhenphysicalexamisinsufficientorunreliable.jWhenMohsorotherformsofPDEMAareutilized,RTisnotrecommended.WhenMohsorotherformsofPDEMAarenotutilized,considerRTifmarginsare<1cm.RTcanbeconsideredfortreatmentofpositivemarginsifnotgivenpreviouslyandfurtherresectionisnotfeasible.kNavarrete-DechentC,etal.JAMADermatol2019;155:361-369.lSeeNCCNGuidelinesforSTAGEIVSoftTissueSarcoma(EXTSARC-5).Note:Allrecommendationsarecategory2Aunlessotherwiseindicated.ClinicalTrials:NCCNbelievesthatthebestmanagementofanypatientwithcancerisinaclinicaltrial.Participationinclinicaltrialsisespeciallyencouraged.DFSP-2Version1.2022,11/17/21©2021NationalComprehensiveCancerNetwork(NCCN),Allrightsreserved.NCCNGuidelinesandthisillustrationmaynotbereproducedinanyformwithouttheexpresswrittenpermissionofNCCN.PrintedbyMinTangon3/14/20227:31:17AM.Forpersonaluseonly.Notapprovedfordistribution.Copyright©2022NationalComprehensiveCancerNetwork,Inc.,AllRightsReserved.uberansdexPRINCIPLESOFPATHOLOGY1•Evaluationbyaqualifiedphysicianwithspecificexpertiseinsarcoma/softtissuepathologyordermatopathologyispreferred(ifavailable).•Thespindledcellsarrangedinastoriformorfascicularpatternaretypicallyblandwithminimalcytologicatypia.•ImmunohistochemistryforCD34ismostlypositive,andfactorXIIIanegative.•Fibrosarcomatoustransformation(FS-DFSP)ischaracterizedbytransitionfromstoriformtoaherringbonepattern,withahigherdegreeofcellularitycytologicatypiamitoticactivityhighpowerfieldsHPFsandfrequentlossofCD34immunostaining.2Forequivocallesionsconsiderfluorescenceinsituhybridization(FISH),polymerasechainreaction(PCR),orconventionalcytogeneticstodetecttqqwhichisahallmarkofDFSPFusionofthecollagentypeIalphageneCOLAat17q22,withtheplatelet-derivedormtheoncogenicchimericfusiongeneCOLAPDGFMargincontrolduringexcisionseePrinciplesofExcision[DPSP-B])mayoccasionallybeaidedbyH&EsectionssupplementedbyCD34istry1Currently,noAmericanJointCommitteeonCancer(AJCC)orCollegeofAmericanPathologists(CAP)synopticreportingisdefined.2FS-DFSPshouldbenotedwhenpresentasthemetastaticriskis15%–20%andthepatientshouldbereferredtoacenterwithexpertiseinmanagementofsofttissuesarcomas.Note:Allrecommendationsarecategory2Aunlessotherwiseindicated.ClinicalTrials:NCCNbelievesthatthebestmanagementofanypatientwithcancerisinaclinicaltrial.Participationinclinicaltrialsisespeciallyencouraged.Version1.2022,11/17/21©2021NationalComprehensiveCancerNetwork(NCCN),Allrightsreserved.NCCNGuidelinesandthisillustrationmaynotbereproducedinanyformwithouttheexpresswrittenpermissionofNCCN.DFSP-APrintedbyMinTangon3/14/20227:31:17AM.Forpersonaluseonly.Notapprovedfordistribution.Copyright©2022NationalComprehensiveCancerNetwork,Inc.,AllRightsReserved.uberansdexPRINCIPLESOFEXCISIONEveryeffortshouldbemadetoachieveclearsurgicalmarginsCompletehistologicsurgicalmarginexaminationtoincludereviewofthepheralanddeepmarginisrecommendedwheneverpossibleTumorcharacteristicsincludelongirregularsubclinicalextensionsDebulkingspecimensfromallexcisionsshouldbeexaminedtoidentifyfibrosarcomatoustransformation(FS-DFSP)sincethisisassociatedwithmetastaticpotential.SurgicalApproach:MohsorOtherFormsofPDEMA•SeeNCCNGuidelinesforSquamousCellSkinCancer-PrinciplesofPDEMATechnique.•IfMohsorotherformsofPDEMAareunavailable,considerwideexcision.pReconstructionshouldbedelayeduntilclearmarginshavebeenverifiedtoavoidtheriskoftranslocatingtumorwithintheresectionbedmakingfurthermarginassessmentsinaccurate.Note:Allrecommendationsarecategory2Aunlessotherwiseindicated.ClinicalTrials:NCCNbelievesthatthebestmanagementofanypatientwithcancerisinaclinicaltrial.Participationinclinicaltrialsisespeciallyencouraged.DFSP-BVersion1.2022,11/17/21©2021NationalComprehensiveCancerNetwork(NCCN),Allrightsreserved.NCCNGuidelinesandthisillustrationmaynotbereproducedinanyformwithouttheexpresswrittenpermissionofNCCN.PrintedbyMinTangon3/14/20227:31:17AM.Forpersonaluseonly.Notapprovedfordistribution.Copyright©2022NationalComprehensiveCancerNetwork,Inc.,AllRightsReserved.uberansdexPRINCIPLESOFRADIATIONTHERAPYrmationuvantRTpPositiveMargins/GrossDisease◊50–60Gyforindeterminateorpositivemargins,andupto66Gyforpositivemarginorgrosstumor(2-Gyfractionsperday).◊Fieldstoextendwidelybeyondsurgicalmargin(eg,3–5cm)whenclinicallyfeasible.pNegativeMargins◊WhenMohsorotherformsofPDEMAareutilized,RTisnotrecommended.◊WhenMohsorotherformsofPDEMAarenotutilized,considerRTifmarginsare<1cm.•Recurrence/Metastasis:pRTifnotgivenpreviouslyandfurtherresectionisnotfeasible;50–60Gyforindeterminateorpositivemargins,andupto66Gyforpositivemarginorgrosstumor(2-Gyfractionsperday).pFieldstoextendwidelybeyondsurgicalmargin(eg,3–5cm)whenclinicallyfeasible.Note:Allrecommendationsarecategory2Aunlessotherwiseindicated.ClinicalTrials:NCCNbelievesthatthebestmanagementofanypatientwithcancerisinaclinicaltrial.Participationinclinicaltrialsisespeciallyencouraged.DFSP-CVersion1.2022,11/17/21©2021NationalComprehensiveCancerNetwork(NCCN),Allrightsreserved.NCCNGuidelinesandthisillustrationmaynotbereproducedinanyformwithouttheexpresswrittenpermissionofNCCN.CAT-1Version1.2022,11/17/21©2021NationalComprehensiveCancerNetwork(NCCN),Allrightsreserved.NCCNGuidelinesandthisillustrationmaynotbereproducedinanyformwithouttheexpresswrittenpermissionofNCCN.PrintedbyMinTangon3/14/20227:31:17AM.Forpersonaluseonly.Notapprovedfordistribution.Copyright©2022NationalComprehensiveCancerNetwork,Inc.,AllRightsReserved.uberansdexNCCNCategoriesofEvidenceandConsensusCategory1ategoryBaseduponhigh-levelevidence,thereisuniformNCCNconsensusthattheinterventionisappropriate.seduponlowerlevelevidencethereisuniformNCCNconsensusthattheinterventionisappropriateBaseduponlower-levelevidence,thereisNCCNconsensusthattheinterventionisappropriate.Baseduponanylevelofevidence,thereismajorNCCNdisagreementthattheinterventionisappropriate.Allrecommendationsarecategory2Aunlessotherwiseindicated.MS-1Version1.2022©2021NationalComprehensiveCancerNetwork(NCCN),Allrightsreserved.NCCNGuidelines®andthisillustrationmaynotbereproducedinanyformwithouttheexpresswrittenpermissionofNCCNPrintedbyMinTangon3/14/20227:31:17AM.Forpersonaluseonly.Notapprovedfordistribution.Copyright©2022NationalComprehensiveCancerNetwork,Inc.,AllRightsReserved.NCCNGuidelinesVersion1.2022DermatofibrosarcomaProtuberans DiscussionDiscussionThisdiscussioncorrespondstotheNCCNGuidelinesforDermatofibrosarcomaProtuberans.Lastupdated:Dec16,2014.TableofContentsDiagnosisMS-2TreatmentMS-3Follow-upMS-4ReferencesMS-5MS-2Version1.2022©2021NationalComprehensiveCancerNetwork(NCCN),Allrightsreserved.NCCNGuidelines®andthisillustrationmaynotbereproducedinanyformwithouttheexpresswrittenpermissionofNCCNPrintedbyMinTangon3/14/20227:31:17AM.Forpersonaluseonly.Notapprovedfordistribution.Copyright©2022NationalComprehensiveCancerNetwork,Inc.,AllRightsReserved.NCCNGuidelinesVersion1.2022DermatofibrosarcomaProtuberansOverviewDermatofibrosarcomaprotuberans(DFSP)isanuncommon,low-gradesarcomaoffibroblastoriginwithanincidencerateof4.2to4.5casespermillionpersonsperyearintheUnitedStates.1,2Itrarelymetastasizes.However,initialmisdiagnosis,prolongedtimetoaccuratediagnosis,andlargetumorsizeatthetimeofdiagnosisarecommon.Three-dimensionalreconstructionofDFSP3hasrevealedtumorswithhighlyirregularshapesandfrequentfinger-likeextensions.4Asaresult,incompleteremovalandsubsequentrecurrencearecommon.ThelocalrecurrencerateforDFSPinstudiesrangesfrom10%to60%,whereastherateofdevelopmentofregionalordistantmetastaticdiseaseisonly1%and4%to5%,respectively.5TheNCCNNonMelanomaSkinCancerPanelhasdevelopedtheseguidelinesoutliningthetreatmentofDFSPtosupplementtheirotherguidelinesNCCNGuidelinesforBasalCellan

温馨提示

  • 1. 本站所有资源如无特殊说明,都需要本地电脑安装OFFICE2007和PDF阅读器。图纸软件为CAD,CAXA,PROE,UG,SolidWorks等.压缩文件请下载最新的WinRAR软件解压。
  • 2. 本站的文档不包含任何第三方提供的附件图纸等,如果需要附件,请联系上传者。文件的所有权益归上传用户所有。
  • 3. 本站RAR压缩包中若带图纸,网页内容里面会有图纸预览,若没有图纸预览就没有图纸。
  • 4. 未经权益所有人同意不得将文件中的内容挪作商业或盈利用途。
  • 5. 人人文库网仅提供信息存储空间,仅对用户上传内容的表现方式做保护处理,对用户上传分享的文档内容本身不做任何修改或编辑,并不能对任何下载内容负责。
  • 6. 下载文件中如有侵权或不适当内容,请与我们联系,我们立即纠正。
  • 7. 本站不保证下载资源的准确性、安全性和完整性, 同时也不承担用户因使用这些下载资源对自己和他人造成任何形式的伤害或损失。

评论

0/150

提交评论